Address: Sokolovská 100/94, 186 00 Praha 8 – Karlín,Czech Republic
Tel: 00420 236 080 300
Pharma Inc. , one of the world’s top 20 pharmaceutical companies, employing 15,000 people globally. Formed in 2005 through the merger of Yamanouchi and Fujisawa, Astellas continues to remain committed to developing first-in-class and best-in-class products in key therapeutic areas by combining outstanding R&D with marketing capabilities and continuing growth in the world pharmaceutical market.
Astellas’ key strengths lie in the therapy areas of Transplantation, Urology, Dermatology, Anti-Infectives and Pain Management. In addition, Astellas is committed to developing a portfolio of treatments to fulfil unmet needs in Oncology.
Astellas in the Czech Republic and Slovakia, one of 21 Astellas affiliates across Europe, was established in 1996 as a former Yamanouchi company, and currently employs staff of 90 employees.
Astellas holds in Czech republic very strong position in several therapeutic area such as urology, transplantation and dermatology.
Mr. Chadim, after Astellas was formed from the merger between Yamanouchi and Fujisawa, it became your job to lead its Czech subsidiary. Tapani Sura, your colleague at Astellas Poland, has…
The latest pharma news from Central and Eastern Europe (CEE), including a new report on the disparities between the region’s healthcare systems and those of Western Europe; why US companies…
Roman Grunt, CEO of Quinta Analytica, gives us an overview of the activities of how the Czech firm has managed to attract customers across the country and beyond by positioning…
PharmaBoardroom’s latest report: Healthcare & Life Sciences Review: Czech Republic is available for download now. Home to a USD 3.38 billion pharma market, one of Central and Eastern Europe’s…
Key stakeholders within the Czech medtech industry highlight how medical devices can improve efficiency and quality of care across the country’s healthcare landscape, why greater levels of collaboration are of…
Roman Samiec, general manager of Thuasne Czech Republic, introduces the company as a key competitor in the medical devices field, with their niche products addressing the unmet medical need in…
Miroslav Palát, president of CzechMed, the medical device association in the Czech Republic, and Jiří Pavlíček, who combines the responsibility of Chairman of the association and CEO of the medtech…
Pavla Nevolová, country head of EastHORN in the Czech Republic, shares the historical roots of the now multinational Czech CRO. Nevolová also shares her insights into the recent evolution of…
The Czech Republic boasts a solid clinical research infrastructure and a supportive regulatory environment, meaning that it stands out as one of Central and Eastern Europe’s top destinations for clinical…
In 1996 Jiří Žák, chairman & current CEO of FARMAK, borrowed half a billion Czech crowns to take over a state-owned producer of vitamins for which he had started working…
As one of the few pharma companies in the Czech Republic to offer products across the whole healthcare spectrum, including prescription drugs, generics, over-the-counter (OTC) treatments, and food supplements, the…
Roman Dusil, GM of Pierre Fabre Laboratories in the Czech Republic and Slovakia, shares how the Czech affiliate is ahead of Pierre Fabre’s global transformation of the convergence between the dermo-cosmetic…
Pharma industry stakeholders are generally quick to suggest that the Czech Republic is one of the most over-regulated markets in Europe, with new or innovative therapies facing significant delays before…
See our Cookie Privacy Policy Here
